GBP5 Antibody

What is GBP5 and what cellular functions does it mediate?

GBP5 (Guanylate-binding protein 5) belongs to the GBP family of interferon-inducible GTPases that play crucial roles in cell-autonomous immunity against a diverse range of bacterial, viral, and protozoan pathogens. GBP5 is involved in several important cellular processes:

• Signal transduction pathways, particularly in immune response mechanisms

• Inflammasome assembly regulation, specifically promoting selective NLRP3 inflammasome assembly in response to microbial and soluble agents

• Autophagy regulation in inflammatory responses, as evidenced in ARDS (Acute Respiratory Distress Syndrome) models

• Inhibition of viral infectivity by preventing FURIN-mediated maturation of viral envelope proteins in viruses such as HIV-1, Zika, and influenza A

Unlike other family members, GBP5 hydrolyzes GTP but does not produce GMP as an end product . Following infection, it is recruited to pathogen-containing vacuoles or vacuole-escaped bacteria where it promotes vacuole lysis and subsequent cytosolic release of pathogens, facilitating detection by inflammasomes .

What are the optimal sample preparation methods when using GBP5 antibodies for tissue immunohistochemistry?

For optimal immunohistochemical detection of GBP5 in tissue samples, the following preparation methods are recommended:

• For rat spleen tissue, antigen retrieval with TE buffer at pH 9.0 is suggested as the primary method

• Alternatively, antigen retrieval may be performed with citrate buffer at pH 6.0

• Recommended dilution for IHC applications ranges from 1:250-1:1000

• Fixation protocols should be optimized based on tissue type, with formalin fixation being standard in most published protocols

• For detection of GBP5 in dental pulp tissues, double immunofluorescence has been successfully employed to examine cellular localization

Always validate antibody performance in your specific tissue of interest, as reactivity has been primarily confirmed in human and rat samples .

What are the recommended applications and dilutions for GBP5 antibodies?

Based on validated experimental protocols, GBP5 antibodies can be used in multiple applications with the following recommended dilutions:

It is important to note that these dilutions should be optimized for each experimental system to obtain optimal results, as reactivity can be sample-dependent .

How can GBP5 expression be effectively analyzed as a biomarker in cancer immunotherapy research?

GBP5 has emerged as a potential biomarker for predicting immunotherapy outcomes, particularly for patients receiving immune checkpoint inhibitors (ICIs). For effective analysis:

• RNA-Seq and Transcriptomic Analysis:

  • Use RNA-Seq data to quantify GBP5 expression levels

  • Analyze correlation with immunotherapy response markers

  • Stratify patients into high and low GBP5 expression groups using median expression values

• Protein Detection Methods:

  • Perform IHC on tissue microarrays (TMAs) using validated GBP5 antibodies

  • Calculate an immunoreactive score (IRS) based on staining intensity and percentage of positive cells

  • Consider GBP5 high expression as IRS≥8 and low expression as IRS<7

• Correlation Analysis with Immune Parameters:

  • Evaluate association between GBP5 expression and PD-L1 levels

  • Assess Immunophenoscore (IPS) values in relation to GBP5 expression

  • Analyze T cell inflamed scores which predict anti-PD-1 treatment efficacy

• Predictive Model Development:

  • Integrate GBP5 expression with other immune markers for improved prediction

  • Compare predictive value (AUC) of GBP5 with established markers like PD-L1 (note: in NSCLC, GBP5 showed higher predictive effect with AUC=0.945 compared to PD-L1 with AUC=0.727)

Research has shown that high GBP5 expression is associated with "immuno-hot" tumor phenotypes and better response to immunotherapy in certain cancer types .

What methodological approaches should be used to study the relationship between GBP5 and immune cell infiltration?

To effectively investigate the relationship between GBP5 expression and immune cell infiltration, researchers should employ multiple complementary methodologies:

• Computational Methods:

  • Utilize multiple immune infiltration evaluation algorithms for robust results (e.g., MCPcounter, EPIC, QuanTIseq)

  • Apply Gene Set Enrichment Analysis (GSEA) to evaluate pathway associations

  • Stratify samples into GBP5-High and GBP5-Low groups based on median expression

• Experimental Validation:

  • Perform multiplex immunofluorescence staining to simultaneously detect GBP5 and immune cell markers

  • Use flow cytometry to quantify immune cell populations in relation to GBP5 expression

  • Consider single-cell RNA sequencing to elucidate cell-specific expression patterns

• Statistical Analysis:

  • Compare immune cell proportions between GBP5-High and GBP5-Low groups

  • Assess correlation between GBP5 expression and specific immune cell types

Research findings have demonstrated that GBP5-High tumors show significantly higher levels of:

• B cells, CD4+ T cells, CD8+ T cells, and macrophages

• Cytotoxic lymphocytes and NKT cells

• Expression of cytotoxicity-related genes, chemokines, and antigen-presenting molecules

These methodological approaches provide comprehensive insights into how GBP5 may influence the tumor immune microenvironment and potentially affect immunotherapy outcomes.

What are the critical considerations for using GBP5 antibodies in knockdown/knockout validation experiments?

When designing GBP5 knockdown/knockout validation experiments, researchers should address these critical considerations:

• Antibody Specificity Validation:

  • Confirm specificity using positive and negative controls

  • Validate antibody performance in Western blot against both wildtype and GBP5-knockout lysates

  • Check for cross-reactivity with other GBP family members due to structural similarities

• Knockdown/Knockout Strategy Selection:

  • For transient knockdown, siRNA or shRNA delivered via lentiviral vectors has been successfully employed

  • For stable knockout, CRISPR-Cas9 systems targeting exons with high conservation is recommended

  • Consider inducible systems for studying GBP5's time-dependent functions

• Functional Validation Approaches:

  • Assess GBP5-dependent cellular pathways (e.g., inflammasome activation, autophagy)

  • Measure response to cytokine stimulation, particularly IFN-γ which induces GBP5 expression

  • Evaluate bacterial/viral challenge responses in control vs. knockout cells

• Experimental Controls:

  • Include both technical and biological replicates (minimum three each)

  • Employ scrambled shRNA or non-targeting gRNA controls

  • Consider rescue experiments by reintroducing GBP5 to confirm phenotype specificity

• Readout Selection:

  • For inflammation studies, measure IL-6, IL-8, IL-1β, and COX2 expression

  • For cancer studies, evaluate immune cell infiltration markers

  • For infection models, assess pathogen burden and inflammasome activation

Published studies have reported successful GBP5 knockdown using lentivirus vector-delivered shRNA in human dental pulp stem cells (HDPSCs), which served as an in vitro inflammation model after LPS stimulation .

How can researchers troubleshoot inconsistent GBP5 antibody detection in Western blotting experiments?

When encountering inconsistent GBP5 detection in Western blotting, consider these methodological adjustments:

Following these troubleshooting steps should help achieve consistent and specific detection of GBP5 in Western blotting experiments.

What are the key considerations when designing experiments to study GBP5's role in autophagy regulation?

To effectively investigate GBP5's role in autophagy regulation, particularly in inflammatory contexts, researchers should consider these experimental design elements:

• Model System Selection:

  • Cell culture models: MLE-12 cells have been validated for GBP5 studies in lung inflammation

  • Animal models: LPS-induced mouse ARDS models have demonstrated GBP5 involvement in autophagy regulation

  • Primary cell isolation: Human dental pulp stem cells (HDPSCs) can be used to study GBP5 in inflammatory responses

• GBP5 Manipulation Approaches:

  • Overexpression: Vector transfection for genetic manipulation of GBP5

  • Knockdown: Lentivirus vector-delivered shRNA to reduce endogenous GBP5 expression

  • Induction: IFN-γ priming to upregulate GBP5 expression

• Autophagy Assessment Methods:

  • Protein markers: Measure LC3-I to LC3-II conversion, p62/SQSTM1 levels

  • Imaging techniques: Immunofluorescence staining for autophagosome formation

  • Flux analysis: Combination of lysosomal inhibitors with autophagy markers to assess autophagic flux

• Inflammation Induction Protocols:

  • LPS stimulation has been validated for inducing inflammation in the context of GBP5 studies

  • Measure inflammatory cytokines (IL-6, IL-8, IL-1β) and mediators (COX2) using RT-qPCR and ELISA

  • Assess MPO activity using commercial kits to evaluate neutrophil infiltration

• Experimental Validation:

  • Include appropriate controls for each manipulation

  • Perform both transcriptional (RT-qPCR) and protein expression (Western blot) analyses

  • Use histological assessments (H&E staining) to evaluate tissue structure changes

Research has shown that GBP5 suppression reduced LPS-induced lung inflammation in mice, while GBP5 overexpression diminished the inhibitory impact of LPS on autophagy during ARDS, leading to increased inflammation . This dual role highlights the importance of carefully designing experiments to dissect GBP5's complex functions in inflammation and autophagy.

How should researchers interpret discrepancies in GBP5 expression patterns across different cancer types?

When encountering variations in GBP5 expression patterns across cancer types, consider these analytical approaches:

• Baseline Expression Evaluation:

  • Compare GBP5 expression in tumor tissues versus adjacent normal tissues

  • Note that GBP5 is generally upregulated in tumor tissues compared to para-cancer tissue in NSCLC

  • Consider tissue-specific expression patterns of GBP5 in normal physiology

• Cancer Subtype Analysis:

  • Stratify data by histological subtypes (e.g., adenocarcinoma vs. squamous cell carcinoma)

  • Analyze molecular subtypes based on genomic profiling

  • Assess correlations between GBP5 expression and clinicopathological features

  For example, in NSCLC cohorts, there was no statistical significance between GBP5 expression levels and age, pathological type, TNM stage, T stage, N stage, M stage, or differentiation, except for gender .

• Immune Context Consideration:

  • Evaluate the immunological status of different tumor types

  • Assess correlation with immune infiltration patterns specific to each cancer type

  • Analyze IFN-γ pathway activation, which induces GBP5 expression

• Methodological Variations:

  • Consider differences in detection methods (RNA-seq, microarray, IHC)

  • Account for antibody variability when comparing IHC results across studies

  • Standardize scoring systems for protein expression assessment

• Integrative Analysis:

  • Combine transcriptomic, proteomic, and clinical data

  • Perform pathway enrichment analysis to identify cancer-specific roles

  • Consider multivariate analysis to identify confounding factors

Understanding these contextual factors helps explain why GBP5 might serve as an effective biomarker in some cancer types but not others, and why its prognostic significance may vary across different malignancies.

What statistical approaches are most appropriate for analyzing GBP5 expression as a predictive biomarker for immunotherapy response?

To rigorously analyze GBP5 as a predictive biomarker for immunotherapy response, researchers should employ these statistical approaches:

• Cohort Stratification Methods:

  • Dichotomize patients into GBP5-High and GBP5-Low groups based on median expression

  • Consider quartile division for more granular analysis

  • Evaluate continuous expression values in addition to categorical groupings

• Predictive Performance Metrics:

  • Calculate Area Under the Receiver Operating Characteristic curve (AUC-ROC) to assess discriminative ability

  • Compare predictive performance against established biomarkers like PD-L1

  • In NSCLC studies, GBP5 demonstrated superior predictive value (AUC=0.945) compared to PD-L1 (AUC=0.727)

• Survival Analysis Techniques:

  • Employ Kaplan-Meier curves with log-rank tests to compare survival outcomes

  • Perform Cox proportional hazards regression for univariate and multivariate analyses

  • Include relevant clinical covariates (age, stage, histology) in multivariate models

• Correlation Analysis:

  • Assess Spearman or Pearson correlation between GBP5 and:

    • Immune cell infiltration metrics

    • Expression of immunomodulators

    • T cell inflamed scores

  • For example, GBP5 showed positive correlation with PD-L1 expression in NSCLC (R=0.454, P<0.001)

• Validation Strategies:

  • Perform internal validation using bootstrapping or cross-validation

  • Conduct external validation in independent cohorts

  • Consider meta-analysis when multiple datasets are available

• Composite Biomarker Development:

  • Evaluate the added value of combining GBP5 with other biomarkers

  • Develop and validate prediction models using machine learning approaches

  • Test models in prospective clinical settings when possible

These statistical approaches provide a comprehensive framework for evaluating GBP5's utility as a predictive biomarker for immunotherapy response, enhancing the translational potential of research findings.

What are the emerging applications of GBP5 antibodies in studying viral infection mechanisms?

Recent research suggests several promising directions for using GBP5 antibodies to investigate viral infection mechanisms:

• Viral Restriction Studies:

  • Investigate GBP5's role in restricting viral replication independent of its GTPase activity

  • Explore GBP5's inhibition of FURIN-mediated maturation of viral envelope proteins in HIV-1, Zika, and influenza A viruses

  • Examine potential antiviral properties against emerging viral pathogens

• Inflammasome Regulation:

  • Study how GBP5 mediates virus-induced inflammasome activation

  • Investigate the relationship between viral sensing and GBP5-mediated inflammasome assembly

  • Explore therapeutic potential of modulating GBP5 activity during viral infections

• Interferon Response Dynamics:

  • Analyze the kinetics of GBP5 upregulation following type I and type II interferon stimulation

  • Assess GBP5's contribution to interferon-stimulated gene (ISG) networks

  • Develop live-cell imaging approaches using labeled GBP5 antibodies to track dynamics during infection

• Host-Pathogen Interaction Mapping:

  • Identify viral factors that interact with or antagonize GBP5

  • Perform co-immunoprecipitation studies using GBP5 antibodies to pull down viral protein complexes

  • Map the structural determinants of GBP5-virus interactions

• Therapeutic Development:

  • Screen for small molecules that enhance GBP5's antiviral activities

  • Investigate cell-type specific roles of GBP5 in viral restriction

  • Assess correlation between GBP5 polymorphisms and susceptibility to viral infections

These emerging applications highlight the potential of GBP5 antibodies not only as research tools but also for developing novel antiviral strategies and understanding fundamental aspects of innate immunity against viruses.

How might single-cell analysis techniques enhance our understanding of GBP5's role in immune cell function?

Single-cell analysis technologies offer unprecedented opportunities to investigate GBP5's functions in immune responses with high resolution:

• Single-Cell RNA Sequencing Applications:

  • Map cell type-specific expression patterns of GBP5 across immune populations

  • Identify rare cell populations with unique GBP5 expression profiles

  • Track changes in GBP5 expression during immune cell activation and differentiation

  • Construct pseudotime trajectories to understand GBP5's role in immune cell development

• Spatial Transcriptomics Integration:

  • Correlate GBP5 expression with spatial location in tissues

  • Analyze GBP5-expressing cells in relation to inflammatory niches

  • Combine with multiplexed antibody staining to create spatially resolved immune maps

  • Study GBP5 expression in tissue microenvironments like tumor-immune interfaces

• Mass Cytometry (CyTOF) Approaches:

  • Develop GBP5 antibody conjugates for mass cytometry

  • Simultaneously measure GBP5 expression and phospho-signaling networks

  • Profile GBP5 in relation to activation markers across immune subsets

  • Assess correlations between GBP5 and functional immune cell states

• Multi-omics Integration:

  • Combine single-cell transcriptomics with epigenetic profiling

  • Correlate GBP5 expression with chromatin accessibility

  • Link GBP5 expression to metabolic states of immune cells

  • Integrate proteomics data to validate transcriptional findings

• Functional Single-Cell Assays:

  • Apply single-cell secretion assays to correlate GBP5 with cytokine production

  • Implement CRISPR screens at single-cell resolution to identify GBP5 regulators

  • Develop reporter systems to track GBP5 dynamics in living cells

  • Perform single-cell migration and interaction assays to assess functional consequences